Temasek’s Vertex Ventures leads $42m Series D for anti-lung disease company Holaira


asthma inhaler health medicalTemasek subsidiary Vertex Ventures has led a $42m Series D financing round for anti-lung disease medical device maker Holaira.

Windham Venture Partners, two strategic investors and a string of existing venture capital backers including Morgenthaler Ventures, Split Rock Partners and Versant Ventures also took part in the round.

Holaira is working on a catheter-based system for a procedure called targeted lung denervation, which has the potential to make breathing easier for patients with chronic obstructive pulmonary disease (COPD).

Vertex venture partner Lincoln Chee said, “Until now, COPD patients have had few options for managing their symptoms.

“We believe that Holaira’s proprietary technology enables a fundamental advance in COPD treatment.

“We anticipate that this simple bronchoscopic treatment will provide lasting lung function improvement by opening obstructed airways.”